Key result
Percutaneous VAD support is linked to ~16.5 mL/kg lower stressed blood volume in cardiogenic shock.
Why the study?
Venous return in cardiogenic shock is governed by stressed blood volume (SBV), yet the impact of percutaneous ventricular assist device (PVAD) support on SBV had never been systematically evaluated.
Does percutaneous ventricular assist device (PVAD) support reduce stressed blood volume in patients and experimental models with cardiogenic shock or acute heart failure?
Observational (n=189)
Yes
Does percutaneous ventricular assist device (PVAD) support reduce stressed blood volume in patients and experimental models with cardiogenic shock or acute heart failure?
Percutaneous ventricular assist device support induces an immediate reduction in stressed blood volume in cardiogenic shock, suggesting it modulates autonomic tone and systemic venous return via baroreflex-mediated mechanisms in addition to unloading the left ventricle.
May support PVAD modulation of venous return beyond LV unloading in shock; leaves open outcome benefits pending randomized trials.
Background The percutaneous ventricular assist device (PVAD) is an established mechanical circulatory support modality for cardiogenic shock (CS). While its primary effect is left ventricular unloading, venous return remains a fundamental determinant of systemic hemodynamics. Venous return is governed by stressed blood volume (SBV), yet the impact of PVAD support on SBV has never been systematically evaluated. Purpose To determine whether PVAD modifies SBV in patients with CS and to validate the physiological reproducibility of clinically observed SBV changes in an experimental model using a reverse translational approach. Methods Clinical study: We organized a prospective multicenter registry of patients with CS supported by PVAD therapy (UNLOADERS-PVAD registry, N = 189). SBV was estimated from right atrial pressure (RAP), left atrial pressure (LAP), and CO using a generalized circulatory equilibrium model (Fig. 1A). SBV trends were analyzed at four points: pre-PVAD, just after PVAD, 24-hrs after PVAD, and before PVAD weaning. Temporal changes were assessed using a linear mixed-effects model. Experimental study: Acute heart failure was induced in four anesthetized canines (Beagles, 10.40.3 kg) by coronary microembolization. We implanted PVAD under fluoroscopic guidance. SBV was calculated using the same generalized circulatory equilibrium model as human. Hemodynamic measurements were obtained at minimum support (P1), maximum support (P3–7)), and after returning to minimum support for 30-min at each stage. Results In UNLOADERS-PVAD registry, compared with pre-PVAD, SBV showed significant reduction just after PVAD initiation (p < 0.001) and PVAD achieved a 16.5 mL/kg decrease in SBV from pre-PVAD implantation to before PVAD weaning (p < 0.001) (Fig. 1B). In the canine model, the increase of PVAD support immediately reduced SBV, which returned to baseline after minimum PVAD support, reproducing the clinical findings. In a representative case, plasma epinephrine levels varied inversely with changes in PVAD flow, paralleling SBV dynamics (Fig. 2A). SBV decreased at maximum support and returned to baseline levels upon returning to minimum support in all four animals, demonstrating a consistent directional response. Additionally, SBV demonstrated an inverse relationship with PVAD-induced increases in arterial pressure (r = −0.51) (Fig. 2B), suggesting baroreflex-mediated sympathetic withdrawal and redistribution of venous blood volume. Conclusion PVAD support induces immediate SBV reduction in CS in both clinical and experimental settings. These findings suggest that PVAD therapy not only unloads the left ventricle but also modulates autonomic tone and systemic venous return through baroreflex-mediated mechanisms.Fig.1FIg.2
No takes yet. Share an insight, caveat, or question.
Otake et al. (2026) conducted an observational in Cardiogenic shock (n=189). Percutaneous ventricular assist device (PVAD) support vs. Pre-PVAD baseline was evaluated on Change in stressed blood volume (SBV) (MD -16.5 mL/kg, p=<0.001). Percutaneous ventricular assist device support significantly reduced stressed blood volume by 16.5 mL/kg from pre-implantation to before weaning in cardiogenic shock patients (p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: